SeedtoB Capital

SeedToB Capital is a venture capital firm based in Suwanee, Georgia, founded in 2021. The firm specializes in healthcare technology, with a particular emphasis on artificial intelligence initiatives within the healthcare sector. Despite significant investments in AI applications, many do not reach their full potential, often remaining in pilot or early adopter stages. SeedToB Capital aims to address this challenge by guiding entrepreneurs through the complexities of the healthcare landscape, helping them find the most efficient path to secure Series B funding. The firm is led by seasoned entrepreneurs who previously founded Jvion, which became the largest clinical AI company in the nation before being sold in a significant cash transaction.

Shantanu Nigam

Co-Founder and Managing Partner

Ritesh Sharma

Managing Partner

17 past transactions

OncoLens

Series B in 2024
OncoLens is a healthcare technology company that develops software solutions aimed at improving cancer care coordination and treatment planning. Their primary product is a HIPAA-compliant, mobile and web-based platform that integrates diverse data sets, oncology care teams, and stakeholders onto a single platform. This platform facilitates multi-disciplinary treatment planning, tumor board discussions, life-science commercial efforts, clinical trials enrollment, and payor authorizations. It also incorporates AI-driven clinical decision support capabilities to enhance the quality of cancer patient care.

Shimmer

Seed Round in 2024
Shimmer provides a platform for 1:1 remote ADHD coaching. Our platform matches users to an ADHD coach who helps guide them towards identifying and meeting goals, maintaining a positive approach to change, and improving productivity while providing a source of accountability.

Feel Therapeutics

Venture Round in 2024
Feel Therapeutics is a digital precision medicine company focused on mental health. It develops physiological and digital biomarkers, along with therapeutics, to enhance the diagnosis, management, and care of mental health conditions. The company's flagship product is a data monitoring device, which is a wristband equipped with five embedded sensors that collect biometric data. This data is analyzed using advanced computer science techniques to create digital biomarkers. Feel Therapeutics aims to provide objective data and passive monitoring to help users improve their mental well-being and cultivate lasting positive emotional habits through its proprietary algorithms and medical-grade wearables.

Canid

Seed Round in 2023
Canid is a company focused on improving the vaccination process for pediatricians through innovative technology. It has developed a scanning system that streamlines the management of vaccination records by eliminating manual data entry and automatically uploading vaccine information into state registries. Additionally, Canid provides a dashboard and process tool that offers administrative consulting, automates vaccine workflows, and manages vaccine inventory. By enhancing the efficiency of vaccination record management, Canid enables pediatric practitioners and state officials to concentrate on their core responsibilities, ultimately facilitating better healthcare outcomes for children.

AngelEye Health

Series B in 2022
AngelEye Health is a developer of a tele-engagement platform designed to integrate parents into the care team during their child's stay in neonatal intensive care units (NICUs) and pediatric units. The company offers a comprehensive, HIPAA-compliant solution that includes bedside cameras, patient communication tools, feeding management systems, and targeted educational resources. These services enhance care team workflows and provide families with improved access to their child's treatment plans and progress through any connected device. By fostering meaningful care experiences, AngelEye Health aims to improve family satisfaction, enhance care delivery efficiency, and ultimately elevate the quality of care for patients.

Biotia

Series A in 2022
Biotia, Inc. is a health technology company based in New York, founded in 2016. It specializes in developing software and laboratory technologies that leverage next-generation DNA sequencing and artificial intelligence to enhance infectious disease discovery and management. By providing tailored microbial surveillance, Biotia's innovative solutions enable clinicians and researchers to identify and mitigate pathogens effectively, thereby reducing hospital-acquired infections and improving patient outcomes. The company's technology empowers healthcare professionals to guide treatment decisions proactively, ultimately aiming to prevent illnesses before they occur.

STRIVE

Series A in 2022
STRIVE operates a platform that enhances athletic performance by collecting and analyzing muscle movement data. It employs sensors embedded in compression shorts, using techniques such as surface electromyography (sEMG) and accelerometers to gather information on muscle exertion. This data enables users to monitor muscle activity, track fatigue levels, prevent injuries, and optimize overall performance for elite athletes across various teams and leagues.

Mployer Advisor

Seed Round in 2022
Mployer Advisor is an independent platform designed to assist employers in researching, reviewing, and evaluating insurance brokers. By operating a comprehensive insurance brokerage directory, the company enables employers to find the most suitable insurance brokers for their specific needs. Mployer Advisor provides actionable data that allows users to search and assess available options for selecting insurance advisors, thereby promoting transparency within the insurance brokerage industry. This approach empowers employers to make informed decisions regarding their insurance needs.

curie ai

Seed Round in 2022
Curie AI is a tech-enabled respiratory care company providing virtual personalized disease management through proprietary AI that passively detects symptoms. This approach results in high adherence, reduction in adverse events, cost savings, and improving overall quality of life for people with chronic respiratory conditions

Heading Health

Seed Round in 2022
Heading Health is a technology-enabled mental health platform dedicated to enhancing access to affordable care. The company provides personalized treatment solutions that utilize evidence-based therapeutics and advanced technologies such as transcranial magnetic stimulation, telepsychiatry, and intramuscular ketamine. By leveraging these tools, Heading Health aims to deliver effective and convenient mental health services, helping patients achieve meaningful outcomes and improved well-being.

Zeit Medical

Seed Round in 2021
Zeit Medical is a company focused on advancing the treatment of neurological injuries through innovative technology. Founded in 2019 by Urs Naber and Orestis Vardoulis, the company has developed a specialized headband that continuously monitors the electrical activity of the brain. This device integrates smoothly with existing electroencephalogram (EEG) systems and automates the pre-screening process, facilitating the annotation of extensive datasets. By identifying signature patterns in EEG readings, Zeit Medical enables physicians to diagnose and treat neurological conditions with greater precision, particularly in detecting the onset of strokes.

GritWell

Seed Round in 2021
GritWell Ltd is a digital health platform that specializes in addressing chronic health conditions through a holistic approach. Founded in 2018 and based in San Francisco, the company connects patients with a variety of health professionals, including nutritionists, health coaches, and naturopathic doctors. GritWell's platform facilitates secure video consultations, direct messaging, and online scheduling, allowing for personalized treatment plans and credible advice tailored to individual needs. By focusing on root cause treatment rather than mere symptom management, GritWell employs clinically validated symptom assessments to guide patients toward appropriate care while integrating natural treatment options. This innovative approach aims to improve health outcomes by enabling patients to find practitioners who can address the underlying issues of their chronic symptoms, such as insomnia, migraines, and anxiety.

Moonlight Therapeutics

Series A in 2021
Moonlight Therapeutics, Inc. is a biotechnology company based in Atlanta, Georgia, specializing in the development of targeted, allergen-specific immunotherapy treatments for food allergies. Utilizing its proprietary platform, Targeted Allergen Specific Immunotherapy (TASIS), the company aims to deliver allergens directly to immune cells in the skin, allowing for the treatment of both individual and multiple allergies. Founded in 2017, Moonlight Therapeutics is dedicated to creating safe and effective therapies that enhance the quality of life for individuals suffering from food allergies. One of its notable innovations includes a novel intradermal therapy designed for peanut allergy desensitization, which employs a unique stamp that can be worn for just a few minutes, facilitating effective treatment.

Feel Therapeutics

Seed Round in 2021
Feel Therapeutics is a digital precision medicine company focused on mental health. It develops physiological and digital biomarkers, along with therapeutics, to enhance the diagnosis, management, and care of mental health conditions. The company's flagship product is a data monitoring device, which is a wristband equipped with five embedded sensors that collect biometric data. This data is analyzed using advanced computer science techniques to create digital biomarkers. Feel Therapeutics aims to provide objective data and passive monitoring to help users improve their mental well-being and cultivate lasting positive emotional habits through its proprietary algorithms and medical-grade wearables.

OncoLens

Series A in 2021
OncoLens is a healthcare technology company that develops software solutions aimed at improving cancer care coordination and treatment planning. Their primary product is a HIPAA-compliant, mobile and web-based platform that integrates diverse data sets, oncology care teams, and stakeholders onto a single platform. This platform facilitates multi-disciplinary treatment planning, tumor board discussions, life-science commercial efforts, clinical trials enrollment, and payor authorizations. It also incorporates AI-driven clinical decision support capabilities to enhance the quality of cancer patient care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.